Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2160602 | 0.89 | CCR1 (1.00) | CCR1KCNH2 | |
| SCHEMBL10291652 | 0.89 | CCR1 (0.91) | CCR1KCNH2 | |
| SCHEMBL2159609 | 0.88 | CCR1 (1.00) | CCR1KCNH2 | |
| SCHEMBL2159606 | 0.88 | CCR1 (1.00) | CCR1KCNH2 | |
| SCHEMBL10291998 | 0.88 | CCR1 (0.91) | CCR1KCNH2 | |
| SCHEMBL10291544 | 0.88 | CCR1 (0.77) | CCR1KCNH2 | |
| SCHEMBL2159374 | 0.87 | CCR1 (1.00) | CCR1KCNH2 | |
| SCHEMBL2160509 | 0.87 | CCR1 (1.00) | CCR1KCNH2 | |
| SCHEMBL2159411 | 0.87 | CCR1 (0.81) | CCR1KCNH2 | |
| SCHEMBL2159415 | 0.87 | CCR1 (0.81) | CCR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | CCR1 4/4885KCNH2 4804/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | CCR1 6/4885KCNH2 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.